Delayed – د. فادي فرحات

31 أكتوبر

#chronic myeloid leukemia #CML #Delayed #ENACT #front-line #imatinib #Lebanon #nilotinib #poor response #resistant #second-line

Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon

by Dr. Fadi Farhat 0